Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 85Rituximab 80Peripheral Blood Stem Cell Transplantation 60fludarabine phosphate 58Filgrastim 40Mycophenolic Acid 37Whole-Body Irradiation 35Cyclosporine 35Radiotherapy 33Etoposide 33Busulfan 33Tacrolimus 31Antilymphocyte Serum 28Melphalan 26Methotrexate 22Prednisone 19Bortezomib 19Methylprednisolone 16Cytarabine 16Vincristine 15Lenalidomide 15Flow Cytometry 14Cord Blood Stem Cell Transplantation 13sargramostim 12Doxorubicin 12Bendamustine Hydrochloride 12fludarabine 11Dexamethasone 11Carmustine 11Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell, Marginal Zone × veltuzumab × Clear all
NCT00596804 2021-08-18

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 1/2 Completed
39 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡